<DOC>
	<DOCNO>NCT00531323</DOCNO>
	<brief_summary>The purpose study look whether change directly one medication HIV ( efavirenz ) new medication HIV ( TMC125 ) effect level TMC125 blood , compare TMC125 take without efavirenz take immediately beforehand . The study aim help investigator understand whether safe change directly efavirenz TMC125 ( gap treatment ) patient need treatment . The study investigate blood level TMC125 take twice day .</brief_summary>
	<brief_title>TMC 125 Blood Levels Study</brief_title>
	<detailed_description>Pharmacokinetic parameter TMC125 evaluate TMC125 give without 14-day efavirenz intake precede period order evaluate risk achieve sub therapeutic concentration TMC125 switch straight efavirenz contain regimen Safety tolerability medication also assess question , physical examination laboratory parameter . These perform regular interval drug study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>1 . The ability understand sign write informed consent form , prior participation screening procedure must willing comply study requirement 2 . Male nonpregnant , nonlactating female 3 . Between 18 65 year , inclusive 4 . Body Mass Index ( BMI ) 18 35 kg/m2 , inclusive 5 . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study period least 1 month study 1 . Any significant acute chronic medical illness 2 . Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG clinical laboratory determination 3 . Positive blood screen hepatitis B and/or C antibodies 4 . Positive blood screen HIV1 2 antibody 5 . Current recent ( within 3 month ) gastrointestinal disease 6 . Clinically relevant alcohol drug use ( positive urine drug screen ) history alcohol drug use consider Investigator sufficient hinder compliance treatment , followup procedure evaluation adverse event . Smoking permit , tobacco intake remain consistent throughout study . 7 . Exposure investigational drug placebo within 4 week first dose study drug 8 . Consumption grapefruit , Seville oranges grapefruit Seville orange contain product within 1 week first dose study drug duration study 9 . Use drug , include overthecounter medication herbal preparation , within 2 week prior first dose study drug 10 . Females childbearing potential without use effective nonhormonal birth control method , willing continue practise birth control method least 30 day end treatment period 11 . Previous allergy constituent pharmaceutical administer trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Pharmacokinetic</keyword>
	<keyword>TMC125</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Efavarinz</keyword>
</DOC>